Element Squared LLC Acquires Shares of 48,420 Bristol Myers Squibb Company $BMY

Element Squared LLC bought a new position in Bristol Myers Squibb Company (NYSE:BMY) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 48,420 shares of the biopharmaceutical company’s stock, valued at approximately $2,612,000. Bristol Myers Squibb makes up approximately 1.4% of Element Squared LLC’s portfolio, making the stock its 18th largest holding.

Several other hedge funds also recently made changes to their positions in the company. Dominguez Wealth Management Solutions Inc. boosted its holdings in Bristol Myers Squibb by 0.8% in the fourth quarter. Dominguez Wealth Management Solutions Inc. now owns 22,404 shares of the biopharmaceutical company’s stock valued at $1,208,000 after purchasing an additional 185 shares during the last quarter. McLean Asset Management Corp grew its holdings in Bristol Myers Squibb by 3.1% in the fourth quarter. McLean Asset Management Corp now owns 6,465 shares of the biopharmaceutical company’s stock valued at $369,000 after purchasing an additional 192 shares during the period. Bath Savings Trust Co increased its position in shares of Bristol Myers Squibb by 2.3% in the fourth quarter. Bath Savings Trust Co now owns 8,743 shares of the biopharmaceutical company’s stock valued at $472,000 after buying an additional 198 shares in the last quarter. Albert D Mason Inc. raised its position in Bristol Myers Squibb by 3.0% during the fourth quarter. Albert D Mason Inc. now owns 7,236 shares of the biopharmaceutical company’s stock worth $390,000 after acquiring an additional 213 shares during the period. Finally, CVA Family Office LLC lifted its stake in Bristol Myers Squibb by 2.6% in the 3rd quarter. CVA Family Office LLC now owns 8,959 shares of the biopharmaceutical company’s stock valued at $404,000 after buying an additional 223 shares in the last quarter. 76.41% of the stock is currently owned by institutional investors.

Bristol Myers Squibb News Roundup

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Positive Phase‑3 data for Camzyos in the SCOUT‑HCM adolescent trial could expand the label and support longer‑term revenue upside. SCOUT‑HCM Trial Results
• Positive Sentiment: Janux Therapeutics triggered a $35M milestone under its collaboration with BMY by nominating a development candidate — near‑term cash and partner validation for BMY’s partnered R&D. Janux Milestone
• Positive Sentiment: Unusually large call‑option activity (~66,900 calls) signals speculative bullish positioning by traders anticipating upside moves. Call Option Activity
• Positive Sentiment: Analyst pieces and screens highlight BMY’s history of earnings surprises and argue the company has components that could support an earnings beat next quarter — a sentiment tailwind if results improve. Zacks Coverage
• Neutral Sentiment: Market estimates and long‑term market studies (e.g., HNSCC market growth to ~ $4.5B by 2034) provide attractive addressable‑market context but aren’t immediate catalysts. HNSCC Market Outlook
• Neutral Sentiment: Brokerage consensus remains centered on a “Hold” and the street target (~$61.41) is close to the current price — keeps upside expectations measured. Analyst Consensus
• Negative Sentiment: Insider selling: EVP David V. Elkins sold 30,000 shares at about $61.67 on April 1 (Form 4), trimming his stake ~15.9% — investors sometimes read executive sales as a near‑term negative signal. Insider Form 4
• Negative Sentiment: Sector risk: reports that the U.S. may consider heavy tariffs (up to 100%) on branded/patented drug imports sparked broad healthcare selling and pressured BMY along with peers. Tariffs / Sector Selloff
• Negative Sentiment: Recent quarterly results showed an EPS miss (Feb. 5), which keeps investor focus on near‑term profitability despite FY‑26 guidance; that remains a headwind until earnings execution improves. Earnings Recap

Analyst Ratings Changes

Several research analysts recently commented on the company. Barclays began coverage on Bristol Myers Squibb in a research note on Thursday, February 19th. They issued an “overweight” rating and a $75.00 price objective for the company. Leerink Partners lifted their price target on shares of Bristol Myers Squibb from $54.00 to $60.00 and gave the company an “outperform” rating in a research report on Tuesday, January 13th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Bristol Myers Squibb in a research report on Monday, March 23rd. HSBC upped their price target on Bristol Myers Squibb from $53.00 to $60.00 and gave the stock a “hold” rating in a research note on Tuesday, March 17th. Finally, Piper Sandler reissued an “overweight” rating and issued a $75.00 price objective (up from $66.00) on shares of Bristol Myers Squibb in a research note on Monday, February 23rd. Nine investment analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Bristol Myers Squibb presently has a consensus rating of “Hold” and an average target price of $61.41.

Insider Activity

In other news, EVP David V. Elkins sold 30,000 shares of the company’s stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $61.67, for a total value of $1,850,100.00. Following the completion of the transaction, the executive vice president owned 159,248 shares in the company, valued at approximately $9,820,824.16. This represents a 15.85% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 0.09% of the company’s stock.

Bristol Myers Squibb Trading Down 0.0%

Shares of NYSE:BMY opened at $59.57 on Friday. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $62.89. The company’s 50 day moving average is $59.37 and its two-hundred day moving average is $52.66. The company has a market cap of $121.63 billion, a PE ratio of 17.27, a P/E/G ratio of 0.17 and a beta of 0.27. The company has a current ratio of 1.26, a quick ratio of 1.14 and a debt-to-equity ratio of 2.32.

Bristol Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 EPS for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). The firm had revenue of $12.50 billion for the quarter, compared to analyst estimates of $12.24 billion. Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.The business’s revenue for the quarter was up 1.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.67 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Equities analysts predict that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 1st. Stockholders of record on Thursday, April 2nd will be given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 4.2%. The ex-dividend date is Thursday, April 2nd. Bristol Myers Squibb’s payout ratio is currently 73.04%.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.